Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FGFR2::TACC2 fusion as a novel KIT-independent mechanism of targeted therapy failure in a multidrug-resistant gastrointestinal stromal tumor.

Genes, chromosomes & cancer - 1 Jul 2022

Dermawan Josephine K, Vanderbilt Chad M, Chang Jason C, Untch Brian R, Singer Samuel, Chi Ping, Tap William D, Antonescu Cristina R

Abstract excerpt

Genetic alterations in FGF/FGFR pathway are infrequent in gastrointestinal stromal tumors (GIST), with rare cases of quadruple wildtype GISTs harboring FGFR1 gene fusions and mutations. Additionally, FGF/FGFR overexpression was shown to promote drug resistance to kinase inhibitors in GISTs. However, FGFR gene fusions have not been directly implicated as a mechanism of drug resistance in GISTs. Herein, we report a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gastrointestinal Stromal Tumors
Share to Gene Fusion

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Liver Neoplasms

Share to Proto-Oncogene Proteins c-kit

Share to Receptor, Fibroblast Growth Factor, Type 2

Share to Receptor, Platelet-Derived Growth Factor alpha

Share to Tumor Suppressor Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 35170141
DOI: 10.1002/gcc.23030
PMCID: PMC9194600

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FGFR2::TACC2 fusion as a novel KIT-independent mechanism of targeted therapy failure in a multidrug-resistant gastrointestinal stromal tumor.PMID 35170141Read ↗

Targeted therapies in gastrointestinal stromal tumors.Semantic proximity Read ↗

Targeted therapy and personalized medicine in gastrointestinal stromal tumors: drug resistance, mechanisms, and treatment strategiesSemantic proximity Read ↗

KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors — TORC1/2 Inhibition as Salvage StrategySemantic proximity Read ↗

KIT mutations and expression: current knowledge and new insights for overcoming IM resistance in GIST.Semantic proximity Read ↗

The GIST paradigm: lessons for other kinase‐driven cancersSemantic proximity Read ↗

Gastrointestinal Stromal Tumors: Molecular Mechanisms of Drug Resistance and Advances in Therapeutic Strategies.Semantic proximity Read ↗

A Novel Receptor Tyrosine Kinase Switch Promotes Gastrointestinal Stromal Tumor Drug ResistanceSemantic proximity Read ↗

CCR 20th Anniversary Commentary: A Genetic Mechanism of Imatinib Resistance in Gastrointestinal Stromal Tumor-Where Are We a Decade Later?Semantic proximity Read ↗

Clinicopathologic and molecular spectrum of gastrointestinal stromal tumor (GIST) with NTRK fusion and marked response to Larotrectinib in GIST with NTRK fusion: a case reportSemantic proximity Read ↗

Gastrointestinal Stromal Tumor With Multiple Primary Tyrosine Kinase Mutations-Clinicopathologic and Molecular Characterization.Semantic proximity Read ↗

KIT and BRAF heterogeneous mutations in gastrointestinal stromal tumors after secondary imatinib resistance.Semantic proximity Read ↗

Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.